Atopic Dermatitis Disease Activity and Initiation of Systemic Therapy in the Real-World Setting
An OMNY Health™ Poster
The product of body surface area (BSA) and Physician Global Assessment (PGA) (BSA x PGA) has demonstrated promise as a marker of disease activity (DA) and may be pragmatic in clinical practice given the ease of collection compared to other clinical trial outcome measures.
On May 15 – May 18, 2022, this poster was on display at ISPOR 2022.
Conclusions:
- The BSA x PGA product shows promise as a single metric to measure DA in
AD patients given the ability to predict STI. - Given the complexity of collecting clinical trial outcome measures in AD
patients during routine clinical practice, the BSA x PGA product appears to
be a pragmatic solution in generating real-world evidence for AD.